Blood cancer drug safety tracked over 5 years
NCT ID NCT07162181
First seen Oct 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already completed an earlier study and still benefit from the drug. They receive treatment every 12 weeks for about 5 years, and researchers track any serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer hospital
Beijing, 100142, China
-
Blood Institute of the Chinese Academy of Medical science
Tianjin, 300020, China
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Shanghai East Hospital
Shanghai, 200123, China
-
Sun Yat-sen University Cancer Center
Guangzhou, 510060, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
Conditions
Explore the condition pages connected to this study.